Evogene Ltd. reported a net income of $3.9 million for the third quarter of 2025, a turnaround from a $8.2 million loss in the same period a year earlier. The company’s earnings per share were –$0.31, beating the consensus estimate of –$0.41. Revenue for the quarter totaled $310,000, falling short of the $650,000 estimate, while the nine‑month revenue of $3.5 million declined $0.5 million year‑over‑year.
Operating expenses for the quarter were $2.9 million, a sharp reduction from $5.9 million a year earlier. The cost cut was driven by workforce reductions and the cessation of Biomica and Canonic operations, allowing the company to tighten its expense base while maintaining core research activities.
A $7.9 million gain from discontinued operations—stemming from the sale of Lavie Bio’s activity and the MicroBoost AI for Ag platform to ICL—offset much of the quarterly loss and bolstered cash on hand to $16.0 million as of September 30, 2025.
Revenue decline was largely due to lower seed sales from the Casterra subsidiary and reduced revenue from AgPlenus collaborations. The drop in AgPlenus revenue was partly caused by the absence of a one‑time payment from Bayer that had been received in Q1 2024. Q3 2025 revenue of $1.7 million was slightly lower than the $1.8 million reported in Q3 2024.
Management emphasized a strategic pivot toward the ChemPass AI platform and tighter integration of AgPlenus into core operations. CEO Ofer Haviv said the company is “at a turning point—becoming a focused, AI‑driven company built around our core engine, ChemPass AI.” He added that the recent fundraising and divestitures position Evogene to pursue new collaborations in both pharmaceutical and agricultural sectors.
Investors reacted positively to the earnings beat and the company’s disciplined cost management, while the revenue miss highlighted ongoing challenges in legacy revenue streams. The market’s response underscored confidence in Evogene’s AI‑driven strategy and the financial cushion created by the divestitures.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.